Trial · NCT01505764
The Role of Ghrelin in Cancer Cachexia
NCT01505764, Phase 2, Terminated, VA Office of Research and Development; results first posted 2017-02-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Ghrelin in Cancer Cachexia. Trials, record NCT01505764. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01505764
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Ghrelin in Cancer Cachexia
- NCT number
- NCT01505764
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Cancer Cachexia
- Interventions
- Anamorelin HCl, Placebo
- First posted
- 2012-01-09
- Last updated
- 2018-07-17
- Results first posted
- 2017-02-24
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Body Potassium. | day 84 | percentage change from baseline |
| Secondary | Lean Mass Measured by Densitometry. | day 84 | lean body mass measured by DEXA. Percentage of change day 84-baseline. |
| Secondary | Muscle Strength as Measured by Grip Strength. | day 84 | Dominant hand grip strength day 84 - percent change from baseline |
| Secondary | Body Weight. | day 84 | percent change from day 84-baseline |
| Secondary | Quality of Life. | day 84 | Quality of life as assessed using the FACIT-F Patient Reported Outcome assessments - percentage of change day 84-baseline |
| Secondary | Appetite. | day 84 | Appetite measured by a visual analogue scale ASAS. Percentage of change day84-baseline |
| Secondary | Resting Energy Expenditure. | day 84 | % change between day 84 and baseline |
| Secondary | Functional Performance. | day 84 | Functional performance using stair-climbing power day 84 percent change from baseline |
| Secondary | Body Composition. | day 84 | Body composition as measured by Total body nitrogen. Percentage of change day 84-baseline |
| Secondary | Stair Climbing Power | day 84 | Percent change from baseline |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Body Potassium. | day 84 | cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Lean Mass Measured by Densitometry. | day 84 | only two subjects in each group completed this measure. | percentage change | MEAN |
| SECONDARY | Muscle Strength as Measured by Grip Strength. | day 84 | Cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Body Weight. | day 84 | cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Quality of Life. | day 84 | cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Appetite. | day 84 | cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Resting Energy Expenditure. | day 84 | cancer cachexia patients | percentage change | MEAN |
| SECONDARY | Functional Performance. | day 84 | only two subjects in each group completed this measure. | percentage change | MEAN |
| SECONDARY | Body Composition. | day 84 | only two subjects in each group completed this outcome | percentage change | MEAN |
| SECONDARY | Stair Climbing Power | day 84 | only two subjects in each group completed this outcome | percentage change | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Body Potassium. | Arm 1 (Anamorelin HCl) | -2.13 | Standard Deviation 5.48 | percentage change | |
| Total Body Potassium. | Arm 2 (Placebo) | -0.72 | Standard Deviation 2.11 | percentage change | |
| Lean Mass Measured by Densitometry. | Arm 1 (Anamorelin HCl) | 2.12 | Standard Deviation 3.05 | percentage change | |
| Lean Mass Measured by Densitometry. | Arm 2 (Placebo) | -1.44 | Standard Deviation 0.5 | percentage change | |
| Muscle Strength as Measured by Grip Strength. | Arm 1 (Anamorelin HCl) | 0.31 | Standard Deviation 11.19 | percentage change | |
| Muscle Strength as Measured by Grip Strength. | Arm 2 (Placebo) | -10.45 | Standard Deviation 14.49 | percentage change | |
| Body Weight. | Arm 1 (Anamorelin HCl) | 1.7 | Standard Deviation 3.19 | percentage change | |
| Body Weight. | Arm 2 (Placebo) | -1.8 | Standard Deviation 0.07 | percentage change | |
| Quality of Life. | Arm 1 (Anamorelin HCl) | -6.54 | Standard Deviation 4.9 | percentage change | |
| Quality of Life. | Arm 2 (Placebo) | -14.32 | Standard Deviation 3.78 | percentage change |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 (Anamorelin HCl) | 6 | |
| Overall Study | STARTED | Arm 2 (Placebo) | 3 | |
| Overall Study | COMPLETED | Arm 1 (Anamorelin HCl) | 3 | |
| Overall Study | COMPLETED | Arm 2 (Placebo) | 2 | |
| Overall Study | NOT COMPLETED | Arm 1 (Anamorelin HCl) | 3 | |
| Overall Study | NOT COMPLETED | Arm 2 (Placebo) | 1 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | pain | Nervous system disorders | Arm 1 (Anamorelin HCl) | 1 | 6 | 1 |
| other | pain | Nervous system disorders | Arm 2 (Placebo) | 0 | 4 | 0 |
| other | fatigue | Nervous system disorders | Arm 1 (Anamorelin HCl) | 1 | 6 | 1 |
| other | fatigue | Nervous system disorders | Arm 2 (Placebo) | 0 | 4 | 0 |
| other | cough | Respiratory, thoracic and mediastinal disorders | Arm 1 (Anamorelin HCl) | 0 | 6 | 0 |
| other | cough | Respiratory, thoracic and mediastinal disorders | Arm 2 (Placebo) | 1 | 4 | 1 |
| other | chest pain | Musculoskeletal and connective tissue disorders | Arm 1 (Anamorelin HCl) | 0 | 6 | 0 |
| other | chest pain | Musculoskeletal and connective tissue disorders | Arm 2 (Placebo) | 1 | 4 | 1 |
| other | wheezing | Respiratory, thoracic and mediastinal disorders | Arm 1 (Anamorelin HCl) | 1 | 6 | 1 |
| other | wheezing | Respiratory, thoracic and mediastinal disorders | Arm 2 (Placebo) | 0 | 4 | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 (Anamorelin HCl) | ||
| Total, all-cause mortality | Arm 2 (Placebo) | ||
| Total, other adverse events | Arm 1 (Anamorelin HCl) | 2 | 6 |
| Total, other adverse events | Arm 2 (Placebo) | 1 | 4 |
| Total, serious adverse events | Arm 1 (Anamorelin HCl) | 3 | 6 |
| Total, serious adverse events | Arm 2 (Placebo) | 1 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm 1 (Anamorelin HCl) vs Arm 2 (Placebo): serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01505764
GET https://conductscience.org/api/trials/v1/NCT01505764/results?page=2